- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Xilio Therapeutics secures $35.8 million from warrant exercises | 1 | Investing.com | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Do | Xilio Therapeutics, Inc.: Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates | 874 | GlobeNewswire (Europe) | Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash... ► Artikel lesen | |
| Mo | Xilio Therapeutics erzielt 35,8 Millionen US-Dollar aus Ausübung von Optionsscheinen | 2 | Investing.com Deutsch | ||
| Mo | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 25.11.25 | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Xilio Therapeutics GAAP EPS of -$0.11 misses by $0.08, revenue of $19.07M beats by $0.43M | 2 | Seeking Alpha | ||
| 13.11.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results | 2.171 | GlobeNewswire (Europe) | Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presented... ► Artikel lesen | |
| 13.11.25 | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Xilio presents promising data for tumor-activated immunotherapies | 5 | Investing.com | ||
| 07.11.25 | Xilio reports 40% response rate in colorectal cancer treatment study | 2 | Investing.com | ||
| 07.11.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual ... | 891 | GlobeNewswire (Europe) | 40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing... ► Artikel lesen | |
| 07.11.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 07.11.25 | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.11.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 5 | GlobeNewswire (USA) | ||
| 30.10.25 | Xilio to present vilastobart phase 2 data at SITC annual meeting | 1 | Investing.com | ||
| 30.10.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 03.10.25 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 03.10.25 | Xilio Therapeutics wechselt am Montag an den Nasdaq Capital Market | 2 | Investing.com Deutsch | ||
| 03.10.25 | Xilio Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,460 | 0,00 % | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 26,245 | +12,74 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,805 | -0,18 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 24,250 | -4,19 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen | |
| ALUMIS | 19,550 | +7,59 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 34,580 | -2,87 % | Vifor International AG (CSL Vifor): CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy | FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss
ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/... ► Artikel lesen | |
| ERASCA | 6,705 | +14,81 % | What's Going With Cancer Biotech Erasca Stock On Thursday? | ||
| AVIDITY BIOSCIENCES | 72,39 | +0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARCELLX | 66,31 | +3,11 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| ARS PHARMACEUTICALS | 13,130 | +19,91 % | ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating | ||
| COGENT BIOSCIENCES | 35,330 | -0,67 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| TANGO THERAPEUTICS | 11,820 | +6,92 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen |
XILIO THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,684 Euro und damit -5,49 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.